Molecular drivers of the non- T-cell-inflamed tumor microenvironment in urothelial bladder cancer

Cancer Immunology Research

Volumn 4, Issue 7, 2016, Pages 563-568

  Sweis, Randy F ^a   Spranger, Stefani ^a   Bao, Riyue ^a   Paner, Gladell P ^a   Stadler, Walter M ^a   Steinberg, Gary ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGRAMMED DEATH 1 LIGAND 1; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BATF3; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 2; TUMOR MARKER; UNCLASSIFIED DRUG; WNT7B PROTEIN; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MUSCLE INVASIVE BLADDER CANCER; SOMATIC MUTATION; T LYMPHOCYTE ACTIVATION; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; BLADDER TUMOR; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

B7-H1 ANTIGEN; BETA CATENIN; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOMODULATION; LYMPHOCYTES, TUMOR-INFILTRATING; MUTATION; PPAR GAMMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS;

EID: 84979763259     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0274     Document Type: Article

References (25)

1. Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E86.
2. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long- Term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-8.
3. Bracarda S, Altavilla A, Hamzaj A, SisaniM, Marrocolo F, Del Buono S, et al. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. Semin Oncol 2015;42:495-505.
4. Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic review of immunotherapy in urologic cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015;68:267-79.
5. Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Curr Opin Oncol 2015;27:191-200.
6. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62.
7. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, et al. Chemokine expression in melanoma metastases associated with CD8 T-cell recruitment. Cancer Res 2009;69:3077-85.
8. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune- Active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012;61:1019-31.
9. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Upregulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8() T cells. Sci Transl Med 2013;5: 200ra116.
10. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy. Cancer J 2010;16:399-403.
11. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
12. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013;25:268-76.
13. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007;104:3967-72.
14. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic b-catenin signalling prevents anti- Tumour immunity. Nature 2015;523:231-5.
15. Li B, Dewey CN. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011;12: 323.
16. Wilkerson MD, Hayes DN. Consensus Cluster Plus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 2010;26: 1572-3.
17. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-81..
18. Iyer G, Milowsky MI. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol Oncol 2013;31:303-11.
19. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25:152-65.
20. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
21. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014;111:3110-5.
22. Gajewski TF. The next hurdle in cancer immunotherapy: Overcoming the non-T cell-inflamed tumor microenvironment. Semin Oncol 2015;42: 663-71.
23. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
24. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
25. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-smallcell lung cancer. N Engl J Med 2015;373:123-35.